Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for ischemic cardiomyopathy

Conditions

Ischemic cardiomyopathy

Takuji Kawamura, Emiko Ito, Maki Takeda, Daisuke Yoshioka, Ai Kawamura et al. (9 authors)

Circulation2024-11-12

10.1161/circ.150.suppl_1.4138738

Abstract 10588: Pre-Clinical Study of Induced Pluripotent Stem Cell-Derived Cardiomyocyte Sheet Transplantation for a Cynomolgus Macaque Model of Doxorubicin-Induced Dilated Cardiomyopathy

Tsubasa Mikami, Takuji Kawamura, Masaro Nakae, Kota Suzuki, Eiraku Seiko et al. (7 authors)

Circulation2022-11-08

10.1161/circ.146.suppl_1.10588

Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy

Shigeru Miyagawa, Satoshi Kainuma, Takuji Kawamura, Kota Suzuki, Yoshito Ito et al. (17 authors)

Frontiers in Cardiovascular Medicine2022-08-1689 citations

10.3389/fcvm.2022.950829

Interventions

Human (allogeneic) iPS cell derived-cardiomyocyte sheet transplantation

D017690

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Ischemic cardiomyopathy 2) NYHA class III, IV 3) Patients who can not expect symptomatic improvement with standard treatment for target disease. To be recognized by the third party committee with experts. 4) Ejection fraction <= 35%

Exclusion criteria

Exclusion criteria: 1) Autoimmune disease 2) Allergic or hypersensitive to the immunosuppressant 3) Severe infection 4) Persistent shock due to worsening heart failure 5) Irreversible organ failure other than heart 6) Maignancy 7) Pregnancy 8) Alcoholic or drug addiction in recent six months 9) Allergies or hypersensitivity to animals from which raw materials used 10) Severe pulmonary hypertension

Design outcomes

Primary

Measure	Time frame
Number of patients with improved LVEF compared with preoperative at 26 weeks after transplantation	—

Secondary

Measure	Time frame
1) Number of responders at 26 and 52 weeks after transplantation 2) Evaluation of the following changes before 26 and 52 weeks after transplantation (1) LVEF (2) Left ventricular remodeling (3) Severity of heart failure (4) Rejections (5) Others	—

Contacts

Public ContactTakuji Kawamura

Osaka university hospital

saisentan@tissue.med.osaka-u.ac.jp+81-6-6879-3154

Outcome results

None listed